Form D · Pharmaceuticals

Mirata Pharmaceuticals, LLC

Plymouth Meeting, PA · CIK 0001742436

Offering snapshot reported Jan 14, 2019 · SEC filing

Reported sold
$7.05M
Offering amount: $8M
Investors reported
11
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 4, 2018
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$3.53M$7.05MJun 6, 2018: $3,900,001.00Jun 6, 2018Jan 14, 2019: $7,050,003.00Jan 14, 2019

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$3,900,001 → $7,050,003
  • Reported investors2 → 11

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 14, 2019Amendment$7,050,003$3,150,002vs Jun 6, 201811SEC filing
Jun 6, 2018Initial$3,900,001No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-313995
$5,500,001 was purchased by two non-US investors.

Source: Form D, filed Jan 14, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Matthew Callahan Director, Executive
Maurits Geerlings Director
Brian Hubbard Director
John Johnson Director
Joseph F Lovett Director
Jason Y Zhang Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
610 W. Germantown Pike, Suite 400
Plymouth Meeting, PA, 19462